Results 21 to 30 of about 7,838 (234)

Photoacoustic imaging reveals mechanisms of rapid-acting insulin formulations dynamics at the injection site

Molecular Metabolism, 2022
Objective: Ultra-rapid insulin formulations control postprandial hyperglycemia; however, inadequate understanding of injection site absorption mechanisms is limiting further advancement.
Anjul Khadria, Chad D. Paavola, Konstantin Maslov, Francisco A. Valenzuela, Andrea E. Sperry, Amy L. Cox, Rui Cao, Junhui Shi, Patricia L. Brown-Augsburger, Emmanuel Lozano, Ross L. Blankenship, Ranajoy Majumdar, Scott A. Bradley, John M. Beals, Sunday S. Oladipupo, Lihong V. Wang   +15 more
doaj   +1 more source

Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus

Diabetes, obesity and metabolism, 2023
This study compared the pharmacokinetics, glucodynamics and tolerability following single subcutaneous doses of ultra rapid lispro (URLi) versus Humalog in children (6‐11 years), adolescents (12‐17 years) and adults (18‐64 years) with type 1 diabetes ...
R. Aronson, T. Biester, J. Leohr, Robyn K. Pollom, H. Linnebjerg, E. Labell, Qianyi Zhang, D. Coutant, T. Danne   +8 more
semanticscholar   +1 more source

Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion

Diabetes, obesity and metabolism, 2023
To compare the time to hyperglycaemia recovery after ultra rapid lispro (URLi; Lyumjev®) versus Humalog in a randomized, double‐blind crossover study.
J. Leohr, M. Dellva, E. Labell, D. Coutant, J. Arrubla, L. Plum-Mörschel, E. Zijlstra, Tsuyoshi Fukuda, T. Hardy   +8 more
semanticscholar   +1 more source

Hyperglycemic Hyperosmolar Syndrome With Higher Brain Dysfunction in Which Arterial Spin Labeling Revealed Abnormal Cerebral Blood Flow: A Case Report. [PDF]

Clin Case Rep
ABSTRACT Treatment for hyperglycemic hyperosmolar syndrome (HHS) was initiated for a transferred unconscious patient. Aphasia and agnosia remained even after metabolic improvement. Arterial spin labeling (ASL) indicated increased blood flow in the left temporal and parietal lobes.
Yoshimichi G.
europepmc   +2 more sources

Identification, measurement, and evaluation of blood concentrations of insulin glargine and insulin lispro by UPLC–MS–MS in a dead body suspected of insulin overdose

Journal of Forensic Sciences, 2023
Insulin preparations, which are drug treatments for diabetes, cause fatal hypoglycemia when an overdose is administered. Cases of homicide and suicide using these preparations have been reported and are of great forensic interest.
Sayaka Nagasawa, Rutsuko Yamaguchi, F. Chiba, S. Torimitsu, Hirotaro Iwase   +4 more
semanticscholar   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus. [PDF]

Diabetes Obes Metab
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Bolli GB, Home PD, Lepore M, Riddle MC, Porcellati F, Fanelli CG, Lucidi P, Yki-Järvinen H, Becker RH, Owens DR.   +9 more
europepmc   +2 more sources

Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes

Diabetes Therapy, 2023
Introduction To assess time in range (TIR) (70–180 mg/dL) with postprandial glucose (PPG)-focused titration of ultra rapid lispro (URLi; Lyumjev®) in combination with insulin degludec in people with type 1 diabetes (T1D).
R. Bergenstal, B. Bode, A. Bhargava, Qianqian Wang, Alastair W. Knights, Annette M. Chang   +5 more
semanticscholar   +1 more source

Ultra‐rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double‐blind phase 3 study

Diabetes, obesity and metabolism, 2023
To investigate the efficacy and safety of ultra‐rapid lispro (URLi) versus insulin lispro in predominantly Chinese patients with type 1 diabetes (T1D) in a prospective, randomized, double‐blind, treat‐to‐target, phase 3 study.
Jian-Hua Ma, Xiang Yan, Qiong Feng, Wei Liu, Federico Pérez Manghi, P. García-Hernández, Gui-Xia Wang, Jianwei Xu, Yuan Yuan, Zhi-Guang Zhou   +9 more
semanticscholar   +1 more source

The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes

Cardiovascular Diabetology, 2023
Objective Basal insulin glargine has a neutral effect on cardiovascular risk in type 2 diabetes (T2DM). In practice, basal insulin is often paired with a glucagon-like peptide-1 receptor agonist (GLP1-RA) or meal insulin; however, the cardiovascular ...
Ravi Retnakaran, Jiajie Pu, Chang Ye, Alexandra Emery, Caroline K. Kramer, Bernard Zinman   +5 more
doaj   +1 more source

Continuous glucose monitoring-guided management of capivasertib-associated hyperglycemia: A case series of three patients. [PDF]

J Diabetes Investig
Continuous glucose monitoring (CGM) visualized cyclic glycemic fluctuations associated with the 4‐days‐on/3‐days‐off capivasertib schedule. Compared with off‐treatment days, dosing days showed higher mean sensor glucose, greater coefficient of variation (CV), more time above 250 mg/dL, and lower time in range (TIR; 70–180 mg/dL).
Okumura H, Bouchi R, Ando K, Mizuno H, Sugimoto H, Umamoto K, Kodani N, Ihana-Sugiyama N, Izumi K, Ohsugi M, Ueki K, Shimomura A, Shimizu C, Tanabe A.   +13 more
europepmc   +2 more sources